HRMY - Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage
2024-01-26 15:33:29 ET
Summary
- Alkermes plc expects to have additional results from the phase 1b proof-of-concept study, using ALKS-2680 for the treatment of patients with narcolepsy, in the 1st half of 2024.
- An update on the advancement of a phase 2 study, using ALKS-2680 for the treatment of patients with narcolepsy, is expected in the 1st half of 2024.
- The global narcolepsy drugs market size is projected to reach $6.6 billion by 2030.
- Alkermes has 4 proprietary products it is selling to generate revenue; Net product revenues for Q3 of 2023 reached $380.9 million, which was a 16% year-over-year growth.
Alkermes plc ( ALKS ) has been able to report initial proof-of-concept results from its ongoing phase 1 study in both healthy volunteers and the first 4 patients with narcolepsy type 1 [NT1] at the 2023 World Sleep Congress . The first part of the study dealt with healthy volunteers, which was shown to be tolerable for all doses tested. The second part dealt with the randomized portion of the study, in which all 3 doses of ALKS-2680 resulted in statistically clinically meaningful improvements compared to placebo in terms of wakefulness....
Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage